Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Innocan Pharma reports FY results (SeekingAlpha) +++ INNOCAN Aktie +3,98%

ULTRAGENYX Aktie

 >ULTRAGENYX Aktienkurs 
18.9 EUR    +2.2%    (TradegateBSX)
Ask: 19.5 EUR / 820 Stück
Bid: 19.2 EUR / 840 Stück
Tagesumsatz: 81 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
ULTRAGENYX Aktie über LYNX handeln
>ULTRAGENYX Performance
1 Woche: +9,5%
1 Monat: -6,3%
3 Monate: +8,8%
6 Monate: -28,3%
1 Jahr: -41,8%
laufendes Jahr: +8,8%
>ULTRAGENYX Aktie
Name:  ULTRAGENYX PHARM. DL-,001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US90400D1081 / A1XCY0
Symbol/ Ticker:  UP0 (Frankfurt) / RARE (NASDAQ)
Kürzel:  FRA:UP0, ETR:UP0, UP0:GR, NASDAQ:RARE
Index:  -
Webseite:  https://www.ultragenyx.co..
Profil:  Ultragenyx Pharmaceutical is a biopharmaceutical company focused on identifying, acquiring, developing, and commercializing novel products for treating rare and ultra-rare genetic diseases across North America, Latin America, Europe, the Middle East,..
>Volltext..
Marktkapitalisierung:  1612.49 Mio. EUR
Unternehmenswert:  2090.12 Mio. EUR
Umsatz:  581.65 Mio. EUR
EBITDA:  -432.93 Mio. EUR
Nettogewinn:  -497.55 Mio. EUR
Gewinn je Aktie:  -5.05 EUR
Schulden:  1082.52 Mio. EUR
Liquide Mittel:  375.25 Mio. EUR
Operativer Cashflow:  -402.92 Mio. EUR
Bargeldquote:  1.8
Umsatzwachstum:  5.84%
Gewinnwachstum:  10.89%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  7 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 2.528.159 USD.
Suchwörter:  ULTRAGENYX
Letzte Datenerhebung:  02.04.26
>ULTRAGENYX Kennzahlen
Aktien/ Unternehmen:
Aktien: 96.63 Mio. St.
Frei handelbar: 94.47%
Rückkaufquote: -4.61%
Mitarbeiter: 1371
Umsatz/Mitarb.: 0.42 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 167.37%
Bewertung:
KGV: -
KGV lG: -
KUV: 2.93
KBV: -
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: 78.65%
Gewinnmarge: -85.54%
Operative Marge: -79.63%
Managementeffizenz:
Gesamtkaprendite: -37.91%
Eigenkaprendite: -656.54%
>ULTRAGENYX Peer Group
Gesundheit, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten, Antikörper- Behandlung
 
02.04.26 - 15:36
 Ultragenyx says gene therapy accepted for FDA review again (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
02.04.26 - 14:33
 Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) (GlobeNewswire EN)
 
If approved, UX111 will be the first approved therapy for the treatment of Sanfilippo syndrome Type A, a rare disease affecting young children that leads to progressive, irreversible neurodegeneration and early death...
31.03.26 - 19:45
 Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND (Zacks)
 
RARE's IND for UX016, a novel sialic acid prodrug targeting GNEM, a rare muscle disease, gets accepted by the FDA. The first-in-human study is slated for H2'26....
30.03.26 - 23:30
 RARE Deadline: RARE Investors with Losses in Excess of $100K Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit (PR Newswire)
 
NEW YORK, March 30, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026......
30.03.26 - 16:45
 Ultragenyx gains FDA IND clearance of UX016 for GNE myopathy (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
30.03.26 - 14:33
 Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy (GlobeNewswire EN)
 
Program to be externally funded by a venture philanthropy agreement through clinical proof-of-concept, including the Phase 1/2 study planned to begin in the second half of 2026 Program to be externally funded by a venture philanthropy agreement through clinical proof-of-concept, including the Phase 1/2 study planned to begin in the second half of 2026...
30.03.26 - 09:42
 Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE (PR Newswire)
 
LOS ANGELES, March 30, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or "the Company") (NASDAQ: RARE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5......
30.03.26 - 08:36
 RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm (PR Newswire)
 
LOS ANGELES, March 30, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or "the Company") (NASDAQ: RARE) for violations of §§10(b) and 20(a) of the......
29.03.26 - 14:15
 RARE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Investors of Securities Class Action Deadline on April 6, 2026 (PR Newswire)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like......
28.03.26 - 03:48
 Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline (PR Newswire)
 
NEW YORK and NEW ORLEANS, March 27, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NasdaqGS: RARE) of a class action......
26.03.26 - 15:02
 INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE (PR Newswire)
 
NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or......
25.03.26 - 23:51
 RARE Deadline: RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit (PR Newswire)
 
NEW YORK, March 25, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026......
24.03.26 - 15:33
 Ultragenyx downgraded to neutral at Goldman Sachs on setrusumab data (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
22.03.26 - 13:36
 RARE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 (PR Newswire)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like......
21.03.26 - 03:30
 Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE (PR Newswire)
 
NEW ORLEANS, March 20, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 6, 2026 to file lead plaintiff applications in a securities class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the......
20.03.26 - 21:33
 Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
 
NOVATO, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 10,839 restricted stock units of the company's common stock to two newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of March 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4)....
20.03.26 - 01:12
 RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit (PR Newswire)
 
NEW YORK, March 19, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026......
19.03.26 - 13:24
 INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - RGRD Law (PR Newswire)
 
SAN DIEGO, March 19, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023 and December 26, 2025, all dates inclusive (the "Class Period"), have until Monday, April 6,......
18.03.26 - 14:42
 LEVI & KORSINSKY, LLP: FRAUD-ON-THE-MARKET DOCTRINE UNDERPINS ULTRAGENYX PHARMACEUTICAL SECURITIES CLASS ACTION (PR Newswire)
 
Know Your Rights: How Basic Inc. v. Levinson Enables Investor Recovery NEW YORK, March 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP announces that a securities class action has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). YOU MAY BE AFFECTED IF YOU: Purchased......
17.03.26 - 14:06
 RARE Shareholder Alert: Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm (PR Newswire)
 
NEW YORK, March 17, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). Shareholders who purchased shares of RARE during the class period listed are encouraged to contact the firm regarding possible lead......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Don′t marry, be happy. - Hera Lind
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!